Rinzimetostat

Rinzimetostat (ORIC-944) is a small-molecule drug developed by ORIC Pharmaceuticals. The sponsor describes its target as PRC2 (EED subunit), which OnCo does not yet have a target page for. The sponsor states: A potent and selective allosteric inhibitor of Polycomb Repressive Complex 2 (PRC2) acting via the EED subunit, intended to provide advantages over EZH2-targeted approaches. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07723248 (A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)), in prostate cancer. The largest, NCT07723248, plans to enrol 600 participants with primary completion expected 2028-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.